Drug discovery
Rank therapeutic targets and confront them with your DEGs. Ranks druggable targets across 33 TCGA indications, then tests whether the well-ranked ones are enriched among the differentially expressed genes you actually measured.
Pricing on request · billed annually · works with Starter, Pro and Enterprise
Why it exists
A target list and a DEG list, finally in the same place
Target prioritisation usually happens in one team, on public cohort data, and differential expression happens in another, on the experiment that was actually run. The two lists meet late, informally, and usually in a spreadsheet.
This module puts the ranking next to your own result and asks the question that matters: of the targets that rank well for this indication, how many are moving in your data? An enrichment, not a coincidence — and a cited report for the candidates that survive.
Start from the indication, or start from your data
Mode A
Rank an indication
Pick one of the 33 TCGA indications — or leave it empty to rank pan-cancer — and get an ordered list of druggable targets with a cited report for the leaders. No data of your own required.
- 33 TCGA indications, or pan-cancer
- Default oncology scoring profile
- Cited report for the top candidates
Mode B
Confront your comparison
Take a comparison you have already run in GenoLens, turn its DEGs into a signature, and test it against the ranking. This is the mode that connects the module to the rest of the platform.
- Signature built from your own up- and down-regulated genes
- Enrichment of well-ranked targets among your DEGs
- Report scoped to the candidates your data supports
From your DEGs to a ranked shortlist
The steps below run automatically. They are worth knowing because each one refuses to guess: a missing replicate count stops the run rather than being filled in, and an empty direction is never sent as if it were a real result.
- Gene symbols expected
Your comparison
Up- and down-regulated genes from a comparison you have already analysed in GenoLens.
- Up to 1 000 genes per condition
Signature
The DEGs become a two-condition signature. Replicate counts are read from the analysis, never assumed, and an empty direction is refused rather than sent.
- ~15 000 genes ranked per indication
Ranking
Targets are ranked for the chosen indication — one of 33 TCGA projects, or pan-cancer — under the oncology scoring profile.
- Cited report for the top candidates
Confrontation
The ranking is tested against your signature: are the well-ranked targets enriched among the genes you actually measured as changed?
The guards are the feature
Target ranking is easy to run and easy to run wrongly. These checks exist because each of them, left out, produces a confident answer from an input that does not support it.
Replicates are read, not assumed
The replicate count per condition comes from the analysis that produced the comparison. If it cannot be established, the run stops instead of proceeding on a guess.
Truncation is reported
A signature is capped at 1 000 genes per condition, most significant first. When that cap bites you are told, rather than quietly receiving a partial result.
Identifiers are checked
Rankings are keyed on gene symbols. If more than 80 % of your identifiers look like Ensembl IDs, you get a warning before the run rather than an empty overlap after it.
What it needs
A comparison with gene symbols. Ensembl-only identifiers are flagged before the run.
Rankings are computed by a dedicated service and are not public. See how biotech and pharma teams use GenoLens around this module on use cases.
Other modules
Modules combine — each one adds to the same comparison
Talk to us
Test your DEGs against a ranked target list
Bring a comparison and an indication. We will run the confrontation on your own data and walk you through what came back.